Help | Contact Us
NukeWorker.com
NukeWorker Menu Astatine-211 targets blood-borne cancers in Seattle clinical trials
« previous next »
Pages: [1]   Go Down

Author Topic: Astatine-211 targets blood-borne cancers in Seattle clinical trials  (Read 312 times)

0 Members and 1 Guest are viewing this topic.

Offline Marlin

  • Forum Staff
  • *
  • Posts: 18990
  • Karma: 5147
  • Gender: Male
  • Stop Global Whining!!!
Astatine-211 targets blood-borne cancers in Seattle clinical trials
« on: Sep 14, 2022, 10:47 »
Astatine-211 targets blood-borne cancers in Seattle clinical trials

To deliver doses of At-211 to patients in the afternoon, scientists must begin producing At-211 in the cyclotron at midnight, bombarding a bismuth target with alpha particles from a helium source for six to seven hours. Up to 130 millicuries of At-211 are required to produce a dose of At-211.

https://www.ans.org/news/article-4305/astatine211-targets-bloodborne-cancers-in-seattle-wash-clinical-trials/
Logged
Pages: [1]   Go Up
« previous next »
 


NukeWorker ™ is a registered trademark of NukeWorker.com ™, LLC © 1996-2025 All rights reserved.
All material on this Web Site, including text, photographs, graphics, code and/or software, are protected by international copyright/trademark laws and treaties. Unauthorized use is not permitted. You may not modify, copy, reproduce, republish, upload, post, transmit or distribute, in any manner, the material on this web site or any portion of it. Doing so will result in severe civil and criminal penalties, and will be prosecuted to the maximum extent possible under the law.
Privacy Statement | Terms of Use | Code of Conduct | Spam Policy | Advertising Info | Contact Us | Forum Rules | Password Problem?